

Keytruda® (pembrolizumab) – Expanded indication

- On January 8, 2020, Merck announced the FDA approval of Keytruda (pembrolizumab), for the
 treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle
 invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who
 are ineligible for or have elected not to undergo cystectomy.
- Keytruda is also approved for other urothelial carcinoma indications, melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, microsatellite instability-high cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, and endometrial carcinoma.
- The approval of Keytruda for the expanded indication was based on data from KEYNOTE-057, an
 open-label, single-arm trial in 96 patients with BCG-unresponsive, high-risk, NMIBC. Patients
 received Keytruda until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or
 progressive disease. The major efficacy outcome measures were complete response and duration
 of response.
 - The complete response rate was 41% (95% CI: 31, 51). The duration of response was 16.2 (range: 0.0+, 30.4+).
- The recommended dose of Keytruda for the treatment of high-risk BCG-unresponsive NMIBC is 200
 mg administered as an intravenous infusion over 30 minutes every 3 weeks until persistent or
 recurrent high-risk NMIBC, disease progression or unacceptable toxicity, or up to 24 months in
 patients without disease progression.
- Refer to the Keytruda drug label for dosing for all its other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.